Flares during long-term entecavir therapy in chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 11, 2016, Pages 1882-1887

  Chi, Heng ^a   Arends, Pauline ^a   Reijnders, Jurriën G P ^a   Carey, Ivana ^b   Brown, Ashley ^c   Fasano, Massimo ^e   Mutimer, David ^d   Deterding, Katja ^f   Oo, Ye H ^d   Petersen, Jörg ^g   van Bommel, Florian ^h   de Knegt, Robert J ^a   Santantonio, Teresa A ^e   Berg, Thomas ^h   Welzel, Tania M ⁱ   Wedemeyer, Heiner ^f   Buti, Maria ^j   Pradat, Pierre ^k   Zoulim, Fabien ^k   Hansen, Bettina E ^a   Janssen, Harry L A ^a,l   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF FOGGIA   (Italy)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g DEPARTMENT OF CARDIOLOGY   (Germany)

^h UNIVERSITY HOSPITAL LEIPZIG   (Germany)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k HOSPICES CIVILS DE LYON   (France)

^l TORONTO GENERAL HOSPITAL   (Canada)

more..

Author keywords

ALT; chronic hepatitis B; entecavir; flare; nucleos(t)ide analogue

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CHRONIC HEPATITIS B; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION; SEROCONVERSION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; ENZYMOLOGY; FOLLOW UP; GENETICS; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOMARKERS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED;

EID: 84996599829     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13377     Document Type: Article

References (26)

1. Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 2008; 359: 1486–500.
2. European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167–85.
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–2.
4. Bertoletti A, Maini M, Williams R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Res. 2003; 60: 61–6.
5. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650–2.
6. Flink HJ, Sprengers D, Hansen BE et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005; 54: 1604–9.
7. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635–9.
8. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009–22.
9. Zhang NP, Reijnders JG, Perquin M, Hansen BE, Janssen HL. Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. J. Viral Hepat. 2011; 18: e252–7.
10. Chi H, Hansen BE, Yim C et al. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment. Pharmacol. Ther. 2015; 41: 867–76.
11. Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503–14.
12. Manns MP, Akarca US, Chang TT et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin. Drug Saf. 2012; 11: 361–8.
13. Arends P, Sonneveld MJ, Zoutendijk R et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut 2015; 64: 1289–95.
14. Sonneveld MJ, Zoutendijk R, Flink HJ, Zwang L, Hansen BE, Janssen HL. Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin. Infect. Dis. 2013; 56: 100–5.
15. Tsai SL, Chen PJ, Lai MY et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J. Clin. Invest. 1992; 89: 87–96.
16. Boni C, Laccabue D, Lampertico P et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963–973 e969.
17. Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7: 20–3.
18. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889–96.
19. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256–63.
20. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567–72.
21. Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J. Hepatol. 2014; 61: 1407–17.
22. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008; 359: 2442–55.
23. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 2003; 39: 595–605.
24. Zeuzem S, Gane E, Liaw YF et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 2009; 51: 11–20.
25. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol. 2010; 53: 348–56.
26. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521–31.